Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to -$0.88.

  • Enanta Pharmaceuticals' EPS (Basic) rose 3529.41% to -$0.88 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.84, marking a year-over-year increase of 2992.7%. This contributed to the annual value of -$3.84 for FY2025, which is 2992.7% up from last year.
  • Enanta Pharmaceuticals' EPS (Basic) amounted to -$0.88 in Q3 2025, which was up 3529.41% from -$0.85 recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year EPS (Basic) high stood at -$0.85 for Q2 2025, and its period low was -$1.86 during Q2 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' median EPS (Basic) value was -$1.33 (recorded in 2023), while the average stood at -$1.32.
  • The largest annual percentage gain for Enanta Pharmaceuticals' EPS (Basic) in the last 5 years was 9991.71% (2021), contrasted with its biggest fall of 26333.33% (2021).
  • Over the past 5 years, Enanta Pharmaceuticals' EPS (Basic) (Quarter) stood at -$1.48 in 2021, then grew by 6.08% to -$1.39 in 2022, then decreased by 13.67% to -$1.58 in 2023, then surged by 33.54% to -$1.05 in 2024, then grew by 16.19% to -$0.88 in 2025.
  • Its last three reported values are -$0.88 in Q3 2025, -$0.85 for Q2 2025, and -$1.06 during Q1 2025.